Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-11
2000-11-14
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3135
Patent
active
061471097
ABSTRACT:
A new use for HMG-CoA reductase inhibitors is provided. In the instant invention, HMG-CoA reductase inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity through a mechanism other than preventing the formation of oxidative-LDL. As a result, HMG-CoA reductase inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
REFERENCES:
patent: 3983140 (1976-09-01), Endo et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4351844 (1982-09-01), Patchett et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4686237 (1987-08-01), Anderson
patent: 4739073 (1988-04-01), Kathawala
patent: 4912107 (1990-03-01), Kleinschroth et al.
patent: 4965200 (1990-10-01), Chen et al.
patent: 5030447 (1991-07-01), Joshi et al.
patent: 5084482 (1992-01-01), Hirsch et al.
patent: 5116870 (1992-05-01), Smith et al.
patent: 5135935 (1992-08-01), Alberts et al.
patent: 5180589 (1993-01-01), Joshi et al.
patent: 5273995 (1993-12-01), Roth
patent: 5298497 (1994-03-01), Tschollar et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5385940 (1995-01-01), Moskowitz
patent: 5428070 (1995-06-01), Cooke et al.
patent: 5470832 (1995-11-01), Gibbs et al.
patent: 5475029 (1995-12-01), Bradfute et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5519035 (1996-05-01), Maiese et al.
patent: 5530001 (1996-06-01), Nakajima et al.
patent: 5543430 (1996-08-01), Kaesemeyer
patent: 5545636 (1996-08-01), Heath, Jr. et al.
patent: 5565448 (1996-10-01), Nambi et al.
patent: 5591772 (1997-01-01), Lane et al.
patent: 5593971 (1997-01-01), Tscholler et al.
patent: 5602098 (1997-02-01), Sebti et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5622985 (1997-04-01), Olukotun et al.
patent: 5723456 (1998-03-01), Jirousek et al.
patent: 5756453 (1998-05-01), Vedder et al.
patent: 5767160 (1998-06-01), Kaesemeyer
patent: 5830910 (1998-11-01), Mattson
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5945452 (1999-08-01), Cooke et al.
patent: 5968983 (1999-10-01), Kaesemeyer
Blauw, G.J., et al., "Stroke, Statins, and Cholesterol: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials With HMG-CoA Reductase Inhibitors" Stroke 28(5):946-950 (1997).
Boston Globe "Statins Found to Cut Risk of Stroke: Cholesterol Drugs Curbed Death Rate" (Jul. 23, 1997).
Bult, H., "Nitric Oxide and Atherosclerosis: Possible Implications for Therapy" Mol. Med. Today 2(12):510-518 (1996), Abstract.
Byington, R.P., et al., "Reduction in Cardiovascular Events During Pravastatin Therapy: Pooled Analysis of Clinical Events of the Pravastain Atherosclerosis Intervention Program" Circulation 92(9):2419-2425 (1995).
Casino, P.R., et al., "The Role of Nitric Oxide in Endothelium-Dependent Vasodilation of Hypercholesterolemic Patients" Circulation 88(6):2541-2547 (1993), Abstract.
Cooke, J.P., et al., "Nitric Oxide Synthase: Role in the Genesis of Vascular Disease" Annu. Rev. Med. 48:489-509 (1997), Abstract.
Crouse, J.R., et al., "Reductase Inhibitor Monotherapy and Stroke Prevention" Arch. Intern. Med. 157:1305-1310 (1997).
Dusting, G.J., "Nitric Oxide in Coronary Artery Disease: Roles in Atherosclerosis, Myocardial Reperfusion and Heart Failure" EXS 76:33-55 (1996), Abstract.
Glaid, A., et al., "Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension" New Eng. J. Med. 333(4):214-221 (1995).
Hebert, P.R., et al., "Cholesterol-Lowering Reduces Risks of Stroke and Total Mortality" Circulation 94 Suppl 1:I-744 (1996) Abstract 4351.
Herbert, P.R., et al., "Cholesterol Lowering and the Risk of Stroke" Arch. Intern. Med. 156:214-215 (1996).
Hislop, A., et al., "Endothelial Nitric Oxide Synthase in Hypoxic Newborn Porcine Pulmonary Vessels" Arch Dis Child Fetal Neonatal Ed., 77(1):F16-22 (Jul. 1997), Abstract.
Jessup, W., "Oxidized Lipoproteins and Nitric Oxide" Curr. Opin. Lipidol. 7(5):274-280 (1996), Abstract.
Laufs, U., et al., "Neue Erkenntnisse uber die Wirkung von HMG-CoA-Reduktase-Hemmern" Dtsch. Med. Wschr. 122:1255-1259 (1997).
Macdonald, P., et al., "The Role of Nitric Oxide in Heart Failure. Potential for Pharmacological Intervention" Drugs Aging 8(6):452-458 (1996), Abstract.
Martinez-Riera, A., et al., "Primary Prevention of Stroke" New Engl. J. Med. 334(17):1138-1139 (1996).
Massoudy, P. et al., "Cardioprotection by Cyclosporine A in Experimental Ischemia and Reperfusion--Evidence for a Nitric Oxide-Dependent Mechanism Mediated by Endothelin" Mol. Cell Cardio. 29, 535-544 (1997).
Munzel, T., et al., "The Physiology and Pathophysiology of the Nitric Oxide/Superoxide System" Herz 22(3):158-172 (1997), Abstract.
O' Driscoll, G., et al., "Simvastatin, an HMG-Coenzyme A Reductase Inhibitor, Improves Endothelial Function within 1 Month" Circulation 95(5):1126-1131 (1997), Abstract.
Rector, T.S., et al., "Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients with Heart Failure" Circulation 93(12):2135-2141 (1996), Abstract.
Sacks, F.M., et al., "The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels" New Engl. J. Med. 335(14):1001-1009 (1996)verage Cholesterol Levels.
Samdani, A.F., et al., "Nitric Oxide Synthase in Models of Focal Ischemia" Stroke 28(6):1283-1288 (1997), Abstract.
Sartor, G., et al., "Simvastatin Treatment of Hypercholesterolemia in Patients with Insulin Dependent Diabetes Mellitus" Int. J. Clin. Pharmacol. Ther. 33(1):3-6 (1995), Abstract.
Stroes, E., et al., Tetrahydrobiopterin Restores Endothelial Function in Hypercholesterolemia J. Clin. Invest. 99(1):41-46 (1997), Abstract.
Wolf, A., et al., "Dietary L-Arginine Supplementation Normalizes Platelet Aggregation in Hypercholesterolemic Humans" J. Am. Coll. Cardiol. 29(3):479-485 (1997), Abstract.
Yokoyama, M., et al., "Regulation of Nitric Oxide Synthase Gene Expression by Cytokines" J. Card. Fail. 2(4 Suppl):S179-S185 (1996), Abstract.
English Translation of Laufs, U., et al., "Neue Erkenntnisse u ber die Wirkung von HMG-CoA-Reduktase-Hemmern" Dtsch. Med. Wschr. 122:1255-1259 (1997).
O'Driscoll et al., "The HMG-CoA Reductase Inhibitor, Simvastatin, Improves Endothelial Function Within One Month," Circulation, vol. 94, No. 8, 1996, p. 1-401.
Endres et al., "Stroke Protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors Mediated by Endothelia Nitric Oxide Synthase," Proc. Natl. Acad. Sci. USA, vol. 95, Jul. 1998, pp. 8880-8885.
Endres et al., "Simvastatin Pretreatment Protects from Focal Cerebral Ischemia," Stroke, vol. 29, No. 1, Jan. 1998, p. 325.
Di Napoli et al., "Simvastatin Exerts a Direct Anti-Ischemic Effect: Evidence of a Nitric-Oxide Mediated Cardioprotection," Eur. Heart J., vol. 19, Aug. 1998, p. 124.
Laufs et al., "Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-Mediated Down-Regulation of Endothelial Nitric Oxide Synthase," J. Biol. Chem., vol. 272, No. 50, Dec. 12, 1997, pp. 31725-31729.
PCT International Search Report.
Laufs et al., "Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase," The Journal of Biological Chemistry, vol. 273, NO. 37, pp. 24266-24271, Sep. 11, 1998.
Lopez-Ongil et al., "Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells," American Journal of Physiology, vol. 271, No. 3, pp. H1072-H1078, Sep.
Endres Matthias
Laufs Ulrich
Liao James K.
Moskowitz Michael A.
Jordan Kimberly
The Brigham and Women's Hospital, Inc.
The General Hospital Corporation
LandOfFree
Upregulation of Type III endothelial cell Nitric Oxide Synthase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Upregulation of Type III endothelial cell Nitric Oxide Synthase , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Upregulation of Type III endothelial cell Nitric Oxide Synthase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065856